New injection SZ1003 tested in Last-Resort liver cancer patients
NCT ID NCT07201064
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage trial will test the safety and tolerability of a new drug called SZ1003 in 12 adults with advanced hepatocellular carcinoma who have already tried and failed at least two standard treatments. Participants receive the drug by infusion every two weeks, and researchers will monitor for side effects and any signs that the tumors shrink or stop growing.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
SZ1003 injection
What this could lead to
If it works, this could point toward a new treatment option for advanced liver cancer patients who have run out of standard therapies.
What could go wrong
This is a very early, small Phase 1 trial with only 12 people, focused on safety. It is too soon to know if SZ1003 will effectively shrink tumors or improve survival.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED HEPATOCELLULAR CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••